Thirty-five men with intermediate/high-risk clinically localized PCa were randomly assigned to goserelin combined with dutasteride ( ZD ) , bicalutamide and dutasteride ( ZBD ) , or bicalutamide , dutasteride , and ketoconazole ( ZBDK ) for 3 months before prostatectomy .